Peng Lingling, Fan Shujin, Lai Feifei, Lin Yongqing, Wu Hongshi, Guo Zhenbin, Yan Li, Li Shu, Wu Junyan, Ren Meng
Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Ann Med. 2025 Dec;57(1):2488180. doi: 10.1080/07853890.2025.2488180. Epub 2025 Sep 18.
Excess iodine intake due to iodinated contrast media (ICM) infusion during medical examinations is considered as a potential cause of thyroid abnormalities. However, the short-term effects of ICM exposure on patients in a Chinese population are not well elucidated.
In total, 200 patients who received intravenous ICM were enrolled, and their thyroid function was determined before ICM exposure (baseline) as well as 1 week and 1 month after the ICM infusion. The relationship between the peak urinary iodine concentration (UIC) and the contrast agent (CA) dose was then investigated. Three months after ICM exposure, the patients who developed thyroid dysfunction within 1 month of ICM exposure were followed up.
This study included 125 males and 75 females, with a mean age of 56.56 ± 13.89 years old and an average CA dose of 26.93 ± 8.35 g. Patients with thyroid nodules had an increased risk of subclinical hyperthyroidism (OR = 2.1491, 95% CI: 1.0335-71.1880, = 0.0465). Additionally, the urinary iodine level (1658.37 ± 527.47 μg/L) peaked at 1 week after ICM exposure, and the peak level was weakly positively correlated with free thyroxine (FT4) level ( = 0.1531, = 0.0317). Meanwhile, CA dose weakly negatively correlated with anti-thyroid peroxidase antibody (TPOAb) (r=-0.2077, 0.0035). The follow-up results at 3 months after ICM exposure showed that the newly developed abnormal thyroid function within 1 month of ICM exposure had mostly returned to normal.
Patients with thyroid nodules had an increased risk of subclinical hyperthyroidism 1 month after iodine contrast imaging. The effect was transient, and most patients self-recovered without any intervention.
医学检查期间输注碘化造影剂（ICM）导致的碘摄入过量被认为是甲状腺异常的一个潜在原因。然而，ICM暴露对中国人群患者的短期影响尚未得到充分阐明。
总共纳入了200例接受静脉注射ICM的患者，并在ICM暴露前（基线）以及ICM输注后1周和1个月测定其甲状腺功能。然后研究尿碘浓度峰值（UIC）与造影剂（CA）剂量之间的关系。ICM暴露3个月后，对在ICM暴露后1个月内出现甲状腺功能障碍的患者进行随访。
本研究包括125名男性和75名女性，平均年龄为56.56±13.89岁，平均CA剂量为26.93±8.35g。甲状腺结节患者发生亚临床甲亢的风险增加（OR = 2.1491，95%CI：1.0335 - 71.1880，P = 0.0465）。此外，尿碘水平（1658.37±527.47μg/L）在ICM暴露后1周达到峰值，且峰值水平与游离甲状腺素（FT4）水平呈弱正相关（r = 0.1531，P = 0.0317）。同时，CA剂量与抗甲状腺过氧化物酶抗体（TPOAb）呈弱负相关（r = -0.2077，P = 0.0035）。ICM暴露3个月后的随访结果显示，ICM暴露后1个月内新出现的甲状腺功能异常大多已恢复正常。
碘造影成像1个月后，甲状腺结节患者发生亚临床甲亢的风险增加。这种影响是短暂的，大多数患者无需任何干预即可自行恢复。
